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Adjudication of End Points in Studies on Substances
Influencing Haemostasis e an Example from
Vascular SurgeryIn any controlled trial, in blinded ones but even more
important in non-blinded, there must be some form of guar-
antee that outcome is objectively and independently evalu-
ated, and also that outcome is consistent with what is stated
in the study protocol. With this aim an increasing number of
studies today appoint an end point adjudication committee.
It is critical that members of the adjudication
committee are truly independent from the sponsors and
from the steering committee of the study, so that no
suspicion can be raised against the proper medical judge-
ment of the end points. The members should on one hand
represent specialities with competence to adequately
evaluate end points, which are considered important in
the specific study, and the evaluation should be made in
a blinded way. On the other hand, the committee must not
be too large as the members have to meet at regular
intervals, and telephone conferences are rarely possible
because there is a lot of paper work with detailed scrutiny
of patient records and in depth discussions on reported and
recorded findings. In case of end point problems or
unexpected complications falling outside the competence
of the adjudication committee members, they must be free
to consult relevant expertise outside the formal
committee. The members should be respected in the
profession, meaning that they often are of a certain
seniority and with own published research of high standard.
The adjudication committee members should be defined
early in the process of planning a study, as they may have
views on various details from definition of end points to
design of study protocol and report forms of end points. The
logistics and flow charts of the evaluation process must be
simple with the aim of providing the adjudication
committee with data in a rapid manner. This is fundamental
as the classification of end points must be fed back to the
data safety monitoring board or committee (DSMB),
the important task of which is to guarantee the safety of
the individual patients included in a study.1078-5884/$34 ª 2008 Published by Elsevier Ltd on behalf of European
doi:10.1016/j.ejvs.2008.06.030In the publication of study results the members of the
adjudication committee should be listed in an appendix to
secure full transparency, and they should also be allowed to
read the manuscript before submission to guarantee that
end point data are reported in a proper way. Depending on
the work done and their input they could also be part of the
authors.
The authors of this paper have a long experience as
researchers in vascular diseases as well as being members
of adjudication and safety committees in a number of
studies. Our reflections could hopefully help in defining the
task of future end point adjudication committees. Results
concerning the effect of a treatment are usually rather well
defined, which is however not always the case with side
effects. There is also another problem concerning unex-
pected and perhaps rare side effects and complications.
Should a suspicion arise there must be a form for rapid
communication between the adjudication committee and
the DSMB, which has the ethical responsibility to recom-
mend continuation, temporal break, modification of the
study or premature stop of it.
The adjudication committee must meet regularly with
not too long intervals (must be defined in every study and
open for modification) and this means that case record
forms as well as original patient documents, when end
points do occur, must be available without delay (must also
be defined). This important step in study logistics must be
taken very seriously to avoid unnecessary delay in data
delivery. The continuous work of the adjudication
committee during the study prevents accumulation of
problems to be solved when the study is otherwise
finalized.
When studying substances with potential influence on
the haemostatic mechanism, evaluation of bleeding and
bleeding complications is obviously important, but the
definition and classification of those complications are not
easy and bleeding complications are definitely not wellSociety for Vascular Surgery.
704 D.Bergqvistdefined. An attempt has been made under the umbrella of
the International Society of Thrombosis and Haemostasis1
concerning non-surgical patients in studies on venous
thromboembolism. When it comes to surgical treatment it
is more difficult as at least some bleeding is unavoidable
during the surgical procedure. Need for transfusion is often
regarded as a sign of a serious bleeding but indication for
transfusion is open for some subjectivity. An example
from a recent trial points to the necessity of working with
the classification for future studies. A late bleeding from
a vascular anastomosis is life threatening, often a sign of
infection and clinically very serious, but if the patient is
lucky having somebody compressing the bleeding site
immediately and adequately, surgical or endovascular
treatment can be undertaken without the need for a single
transfusion. This bleeding should be regarded as mild
or minor according to most classification systems.
None the less it is very serious and from that point of
view major.
The adjudication committee may have information,
although blinded, which the DSMB does not have. Again
an example. In a recent study we observed an unusually
high incidence of amputations from one or two countries (it
could be centers), which could indicate other indication
criteria than in most centers or than what was intended in
the study. If amputation were to be considered an end point
and the sample size based on a certain frequency of
amputations, a highly increased number in both treatment
arms could distort the study situation and dilute the
possibility to draw relevant conclusions. There may be
several reasons to explain such a situation. Except for
medical ones with true center differences, there may also
be economic incentives with liberal inclusion also of
desolate cases in some centers. It is important that
inclusion and exclusion criteria are very strictly defined to
guarantee a case mix reflecting the intention of the study
and the potential population, where the treatment is
intended to be used, if approved by the authorities.
Another amputation example. What should be done if the
frequency of below and above knee amputations is the end
point and when adjudicating the records there seems to be
high rate of foot amputations? Certainly less dramatic than
a leg amputation but still an amputation, which obviously
will influence the quality of life of the patients.
Summary
In trials on prophylaxis and therapy
 The end point adjudication committee must be inde-
pendent from sponsor and steering committee. Senior researchers are preferable, not too many to
keep the process smooth (2e4 is probably optimal;
maybe 3 in case there is voting).
 The adjudication committee must be blinded.
 Rapid delivery of data, CRFs, hospital records etc. to the
committee must be guaranteed (translated in English).
The translation must be medically as much as linguisti-
cally professional to avoid misunderstandings.
 Protocols must be detailed, end point specific but still
simple.
 Rapid adjudication and classification for feedback to
the DSMB. Speeding up this process is for the safety of
the patients.
 As for the DSMB, the adjudication committee should
meet already during the study (and not only when the
study is finished) in order to suggest corrections on
the input of data and also not to delay the time for
unblinding the results.
 Recruitment of external expertise whenever judged
necessary.
 Definition of end points should be discussed and
approved by the adjudication committee before the
start of the study. Definition must be as exact and
detailed as possible (amputation, stroke, MI, bleeding
etc), but the committee must also be alert on unex-
pected findings.
 The investigator must motivate why an end point or
complication is classified as such. This must be very
transparent from the adjudicators.
 The adjudication committee must be alert if there are
apparent center differences, which could indicate vari-
ations in interpretation of inclusion criteria.
 Possibility to read and have comments on the manu-
script before submission (committee members must
be mentioned in all official documents including the
final manuscript).
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